Table 3.
Association between mutated single markers in pfcrt, pfmdr1, pfdhfr and pfdhps and treatment failure with amodiaquine plus sulphadoxine-pyrimethamine
| Gene | Polymorphism | OR | 95% Confidence Interval | p (LRT) |
| pfcrt | K76T | 2.09 | 0.45–9.70 | 0.31 |
| pfcrt | I326L | 2.64 | 0.58–12.03 | 0.16 |
| pfcrt | N356D | 2.64 | 0.58–12.03 | 0.16 |
| pfcr | A220S | 1.23 | 0.55–2.75 | 0.62 |
| pfmdr1 | N86Y | 7.87 | 1.03–60.36 | <0.01 |
| pfmdr1 | Y184F | § | ||
| pfmdr1 | N1042D | § | ||
| pfdhfr | S108N | 0.74 | 0.22–2.51 | 0.64 |
| pfdhfr | C59R | 2.34 | 0.77–7.14 | 0.11 |
| pfdhps | A437G | 3.44 | 1.40–8.47 | <0.01 |
| pfdhps | K540E | § | ||
OR, odds ratio; LRT, likelihood ratio test; pfcrt, Plasmodium falciparum chloroquine resistance transporter; pfmdr1, Plasmodium falciparum multidrug resistance gene 1; pfdhfr, Plasmodium falciparum dihydrofolate reductase; pfdhps, Plasmodium falciparum dihydropteroate synthase; § mutated alleles were not detected in samples from treatment failure cases